Boston Scientific
Advancing science for life™

SpaceOAR Vue™ Hydrogel

Scan. See. Plan. Treat. **All via CT.**



Introduction

The purpose of this value analysis brief is to illustrate the potential clinical and economic benefits of SpaceOAR Vue Hydrogel. This brief is based on select market research, bench testing, clinical literature, and health economics data.

Background

SpaceOAR Vue Hydrogel is the next-generation version of SpaceOAR™ Hydrogel, and has been designed to provide clinicians, practices, and patients with the added benefit of enhanced visibility under CT imaging.[1] SpaceOAR Vue Hydrogel is intended to create a space between the prostate gland and the rectum (the Organ At Risk, OAR), helping to reduce the radiation dose delivered to the rectum during prostate cancer radiation therapy.[1] SpaceOAR Vue Hydrogel can be visualized under CT imaging offering the following intended benefits:

- The enhanced visibility on a CT scan is designed to help physicians improve contouring accuracy of the prostate and rectum, potentially leading to more accurate treatment plan creations when compared to SpaceOAR Hydrogel.[1]
- The continuous visibility on kV CBCT for the visualization of the target region can enable consistent positioning of patients receiving prostate cancer radiation, through intrafraction assessment of the anatomic geometry to support delivery of treatment to plan.[1]
- It may remove the need for a post-implant MRI scan for institutions that perform CT-only planning.
- It may provide a suitable imaging option for patients with implanted metallic devices who cannot undergo an MRI.

Designed to deliver potential clinical benefit and streamlined experience for patients

- SpaceOAR Vue™ Hydrogel is designed to reduce the radiation dose to the rectum that can cause side effects, such as bleeding, leakage, diarrhea, chronic discomfort and irritation, and fecal incontinence.[2-4]
- May remove the need for the patient to obtain additional MRI scans, decreasing the number of visits to the hospital and potential financial burden to patients (deductible, co-insurance).

Designed to deliver potential operational benefits to providers and staff

- One-time minimally invasive procedure remains in place for the duration of radiation.[1]
- Can be integrated into existing practice patterns, fiducial markers can be implanted via the transperineal approach prior to SpaceOAR™ Hydrogel injection.[1]
- Can streamline workflow as
  - Staff may not have to spend time on getting a preauthorization for an MRI approved.
  - May eliminate the need for MRI fusion verification or special techniques to visualize the hydrogel.

Designed to deliver potential economic impact to institutions

- Covered procedure for patients with Medicare coverage, reimbursement is approved under CPT® code 55874 (transperineal placement of biodegradable material, peri-prostatic single or multiple injections, including image guidance) when performed.[4-6]
- CPT Code 55874 Reimbursement:[1,5,6]
  - The Medicare unadjusted national average 2023 hospital outpatient reimbursement is $4,702, demonstrating an increase of 27% over the past 6 years.
  - Physician Medicare national average 2023 reimbursement in the office setting is $2,950; physician facility reimbursement is $164 or 3.03 work RVUs.
- SpaceOAR Vue Hydrogel may reduce overall treatment costs by reducing the need for a post-implant MRI.
  - Some healthcare institutions have reported that payers do not reimburse for the post SpaceOAR Hydrogel procedure MRI.

Conclusion

SpaceOAR Vue™ Hydrogel is a next-generation hydrogel spacer that is designed to provide physicians enhanced visibility on a CT scan. CT visibility may: support contouring accuracy; facilitate consistent patient positioning; and impact the patient experience by potentially reducing the need for an MRI for treatment planning.

1. Data on file with Boston Scientific.
2. Serrano NA, Kalman NS, Anscher MS. Reducing rectal injury in men receiving prostate cancer radiation therapy: Current perspectives. *Cancer Manag Res*. 2017 Jul;9:339-50.
3. Mariados N, Sylvester J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2015 Aug 1;92(5):971-7.
4. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. *Int J Radiat Oncol Biol Phys*. 2017 Apr 1;97(5):976-85.
5. Centers for Medicare and Medicaid Services. Revisions to Payment Policies under the 2023 Medicare Physician Fee Schedule. https://www.cms.gov/license/ama?file=/files/zip/2023-nfrm-opps-addenda.zip Addendum B, Line 6303, accessed 5/23/2023
6. 2023: Medicare OPPS 2023 Fee Schedule: https://www.cms.gov/license/ama?file=/files/zip/2023-nfrm-opps-addenda.zip Addendum B, Line 6303, accessed 5/23/2023.
7. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. *Clin Adv Hematol Oncol*. 2013 Jan;11(1):14-23.
8. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments [published correction appears in *Cancer*. 2007 May 15;109(10):2155]. *Cancer*. 2007 Feb 1;109(3):518-27.

Boston Scientific
Advancing science for life™

Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.BostonScientific.com

URO-851506-AB JUN 2023